human
metapneumoviru
hmpv
paramyxoviru
first
identifi
pathogen
associ
upper
lower
respiratori
tract
infect
children
seropreval
studi
show
almost
children
acquir
infect
year
age
frequent
reinfect
occur
life
preval
hmpv
infect
among
hospit
children
acut
respiratori
infect
fever
similar
respiratori
virus
clinic
diseas
close
resembl
associ
respiratori
syncyti
viru
infect
rsv
relat
paramyxoviru
prospect
cohort
studi
hmpv
reveal
seropreval
children
hospit
respiratori
tract
infect
patient
requir
supplement
oxygen
requir
intens
care
unit
icu
admiss
lower
respiratori
tract
ill
lrti
caus
hmpv
includ
bronchiol
pneumonia
croup
hmpv
also
associ
acut
otiti
media
well
rare
conjunct
gastroenter
rash
adult
hematolog
malign
hmpv
associ
high
rate
progress
upper
lower
respiratori
tract
diseas
substanti
mortal
treatment
hmpv
mainli
support
anim
data
support
use
bronchodil
corticosteroid
control
trial
done
assess
efficaci
human
popul
ribavirin
nucleosid
analogu
shown
invitro
studi
activ
hmpv
ribavirin
approv
use
treatment
respiratori
syncyti
viru
rsv
often
use
combin
intraven
immunoglobulin
ivig
sever
immunocompromis
individu
prior
descript
clinic
manag
treatment
hmpv
respiratori
tract
infect
pediatr
immunocompromis
popul
includ
children
leukemia
solid
organ
transplant
recipi
avail
describ
hmpv
respiratori
tract
infect
pediatr
immunocompromis
patient
seattl
children
hospit
report
clinic
present
manag
outcom
screen
posit
laboratori
result
hmpv
direct
fluoresc
antibodi
dfa
realtim
reversetranscriptas
polymeras
chain
reaction
rtqpcr
perform
identifi
patient
age
newborn
year
diagnos
seattl
children
hospit
seattl
wa
year
total
patient
posit
hmpv
laboratori
result
perform
retrospect
chart
review
identifi
subset
patient
immunocompromis
condit
defin
immunocompromis
condit
presenc
hematolog
malign
solid
tumor
rheumatolog
diseas
receiv
immunosuppress
therapi
solid
organ
transplant
primari
immunodefici
receipt
chronic
immunosuppress
therapi
receipt
hematopoiet
stem
cell
transplant
hsct
use
electron
chart
review
abstract
sociodemograph
variabl
symptom
laboratori
radiolog
valu
clinic
cours
treatment
outcom
patient
respiratori
specimen
obtain
nasal
wash
patient
suspect
respiratori
viral
infect
attend
physician
bronchoalveolar
lavag
fluid
bal
perform
dfa
perform
use
virusspecif
mous
monoclon
antibodi
chemicon
temecula
ca
rtqpcr
perform
use
previous
publish
method
univers
washington
virolog
laboratori
viral
load
valu
obtain
subset
patient
whose
sampl
test
rtqpcr
estim
viral
load
data
calcul
cycl
threshold
valu
rtqpcr
analysi
use
store
standard
curv
data
hmpv
upper
respiratori
tract
infect
urti
defin
hmpv
document
upper
respiratori
tract
specimen
patient
compat
symptom
absenc
radiograph
clinic
evid
pneumonia
lrti
defin
new
pulmonari
infiltr
presenc
lower
respiratori
tract
symptom
wheez
hypoxia
associ
posit
lower
respiratori
tract
specimen
posit
upper
respiratori
tract
specimen
patient
undergo
bal
neutropenia
defin
absolut
neutrophil
count
cellsml
lymphopenia
defin
lymphocyt
count
cellsml
ageadjust
sever
lymphopenia
lymphocyt
count
cellsml
infect
defin
nosocomi
patient
hospit
within
day
diagnosi
otherwis
classifi
commun
acquir
sever
diseas
defin
requir
icu
stay
andor
use
supplement
oxygen
mortal
attribut
hmpv
defin
death
due
respiratori
failur
pneumonia
hospit
hmpv
diagnos
hmpv
consid
contributor
lung
injuri
data
enter
passwordprotect
excel
spreadsheet
analyz
use
stata
stata
corp
colleg
station
tx
comparison
clinic
characterist
perform
use
fisher
exact
test
categor
variabl
test
unequ
varianc
continu
variabl
studi
approv
seattl
children
hospit
irb
overal
hmpvinfect
immunocompromis
patient
identifi
may
march
characterist
patient
list
tabl
median
age
year
rang
year
major
hematolog
malign
underli
condit
acut
lymphoblast
leukemia
n
nine
solid
tumor
includ
wilm
tumor
n
osteosarcoma
n
ovarian
cancer
n
nine
patient
undergo
hsct
indic
transplant
includ
aplast
anemia
n
sever
combin
immunodefici
scid
n
eight
patient
solid
organ
transplant
recipi
receiv
immunosuppress
therapi
eight
hmpv
infect
acquir
nosocomi
commun
acquir
case
patient
hospit
evalu
hmpv
infect
overal
characterist
hmpv
ill
episod
list
tabl
major
patient
present
fever
n
andor
cough
n
lymphopenia
present
patient
diagnosi
neutropenia
present
patient
present
urti
symptom
alon
progress
lrti
compar
present
fever
urti
children
present
lrti
differ
age
p
presenc
fever
p
cough
p
neutropenia
p
lymphopenia
p
sampl
test
includ
nasal
wash
n
bal
n
n
diagnosi
hmpv
made
dfa
alon
patient
pcr
alon
patient
dfa
pcr
patient
twelv
patient
met
criteria
sever
diseas
admit
intens
care
unit
icu
sever
diseas
like
neutropen
p
otherwis
differ
age
p
hsct
recipi
statu
p
presenc
lymphopenia
p
icu
stay
alon
associ
age
p
presenc
neutropenia
p
lymphopenia
p
though
hsct
recipi
like
requir
icu
stay
p
nine
patient
hsct
recipi
indic
transplant
includ
aplast
anemia
n
scid
n
ewe
sarcoma
n
acut
lymphoblast
leukemia
n
osteopetrosi
n
subset
abnorm
chest
imag
requir
supplement
oxygen
chest
radiograph
comput
tomographi
imag
repres
patient
illustr
figur
patient
three
patient
diagnosi
hmpv
prior
transplant
includ
children
scid
aplast
anemia
gener
polici
institut
delay
transplant
patient
respiratori
tract
infect
howev
case
felt
due
underli
diseas
lack
function
immun
system
patient
would
abl
clear
viral
infect
without
hsct
two
transplant
recipi
subsequ
die
due
hmpv
infect
eight
patient
solid
organ
transplant
recipi
median
time
transplant
hmpv
infect
month
rang
month
none
requir
icu
stay
supplement
oxygen
three
chest
imag
perform
abnorm
chest
radiograph
none
receiv
treatment
ribavirin
ivig
though
death
attribut
hmpv
infect
compar
immunocompromis
patient
solid
organ
transplant
recipi
like
fever
p
cough
p
abnorm
chest
imag
p
classifi
lrti
diseas
initi
clinic
present
p
six
patient
respiratori
sampl
collect
multipl
time
point
median
number
sampl
collect
rang
sampl
median
durat
followup
day
rang
day
type
sampl
primarili
nasal
wash
sampl
also
includ
two
bal
one
sinu
biopsi
one
lung
biopsi
sampl
patient
well
bal
sampl
patient
median
initi
viral
load
estim
copiesml
rang
copiesml
viral
load
data
patient
illustr
figur
patient
patient
patient
die
median
time
initi
final
sampl
day
rang
day
median
chang
viral
load
copiesml
rang
copiesml
patient
surviv
median
time
viral
clearanc
day
rang
day
nine
patient
treat
hmpv
infect
median
age
year
rang
year
patient
includ
hsct
recipi
patient
hematolog
malign
patient
solid
tumor
indic
hsct
includ
aplast
anemia
n
scid
n
ewe
sarcoma
n
eight
treat
patient
fever
cough
abnorm
chest
imag
five
copathogen
identifi
five
hospit
icu
receiv
supplement
oxygen
five
patient
receiv
ribavirin
ivig
receiv
ribavirin
alon
receiv
ivig
alon
hsct
recipi
hmpv
detect
prior
transplant
median
time
prior
transplant
day
rang
day
detect
day
transplant
treatment
ribavirin
ivig
initi
median
day
hmpv
diagnosi
rang
day
sever
patient
receiv
multipl
cours
ribavirin
ivig
treatment
ribavirin
alon
n
initi
day
diagnosi
respect
patient
receiv
ribavirin
receiv
inhal
ribavirin
dose
g
time
daili
cours
receiv
cours
intraven
ribavirin
three
patient
die
respiratori
failur
relat
hmpv
pneumonia
two
death
occur
hsct
recipi
diagnos
hmpv
prior
transplant
figur
patient
one
hsct
recipi
engraft
time
death
engraft
day
prior
death
treat
ribavirin
ivig
third
death
occur
patient
secondari
acut
myelogen
leukemia
salvag
chemotherapi
receiv
hmpvspecif
treatment
figur
patient
hmpv
consid
contribut
factor
death
though
primari
caus
death
thought
progress
median
time
death
day
rang
day
human
metapneumoviru
infect
immunocompromis
patient
popul
associ
high
rate
lrti
present
attribut
mortal
rate
substanti
higher
gener
popul
hmpv
commonli
selflimit
urti
studi
immunocompromis
children
hmpv
classifi
sever
diseas
neutropenia
identifi
signific
risk
factor
diseas
sever
rate
compar
even
higher
previou
rate
report
serious
immunocompromis
adult
patient
similar
retrospect
studi
perform
pediatr
cancer
patient
look
morbid
mortal
relat
respiratori
virus
parainfluenza
viru
associ
lrti
patient
mortal
rate
mix
popul
pediatr
cancer
transplant
patient
similarli
respiratori
syncyti
viru
rsv
associ
lrti
mortal
mix
group
pediatr
transplant
patient
recent
pandem
season
influenza
associ
lrti
rate
mortal
rate
respect
despit
treatment
major
patient
antivir
drug
addit
studi
perform
larger
group
patient
describ
lower
rate
lrti
associ
pandem
sever
case
relat
mortal
prospect
studi
hmpv
adult
hematolog
malign
demonstr
respiratori
tract
infect
attribut
hmpv
major
hsct
recipi
among
hsct
recipi
hmpv
associ
mortal
studi
one
first
describ
present
manag
symptomat
hmpv
infect
immunocompromis
children
present
hmpv
pediatr
solid
organ
transplant
recipi
shown
similar
patient
immunocompromis
condit
fever
cough
common
symptom
also
show
major
immunocompromis
patient
diagnos
hmpv
subsequ
admit
hospit
evalu
initi
present
urti
symptom
go
develop
lrti
howev
clear
differ
present
patient
urti
lrti
term
age
symptom
fever
cough
laboratori
abnorm
underli
condit
would
clearli
identifi
risk
factor
lrti
diseas
guid
decisionmak
interestingli
patient
death
patient
hmpv
pneumonia
diagnos
prior
hsct
patient
howev
underli
diseas
aplast
anemia
scid
made
extrem
unlik
would
abl
clear
viral
infect
without
reconstitut
immun
system
hsct
patient
underw
hsct
subsequ
die
hmpv
pneumonia
despit
use
ribavirin
ivig
support
care
includ
mechan
ventil
icu
stay
patient
continu
detect
viru
within
day
death
institut
well
transplant
center
pediatr
hsct
recipi
screen
respiratori
viral
pcr
prior
transplant
pretranspl
screen
rsv
delay
transplant
adult
effect
reduc
rate
pneumonia
polici
pediatr
patient
delay
transplant
patient
evid
infect
rsv
influenza
adenoviru
hmpv
even
patient
asymptomat
transplant
gener
delay
asymptomat
shed
rhinoviru
bocaviru
coronaviru
studi
enforc
risk
associ
transplant
document
hmpv
viral
shed
diseas
infect
may
result
seriou
diseas
potenti
modal
treat
least
stabil
patient
white
blood
cell
andor
immun
function
return
consid
util
patient
treatment
ivig
ribavirin
current
util
institut
sever
immunocompromis
individu
among
patient
receiv
treatment
demonstr
mortal
rate
compar
mortal
rate
untreat
individu
howev
almost
certainli
reflect
clinic
decisionmak
initi
treatment
individu
sever
diseas
retrospect
studi
identifi
hmpvinfect
immunocompromis
children
screen
laboratori
result
virolog
laboratori
screen
asymptomat
children
may
captur
complet
data
children
evalu
sole
outpati
privat
clinic
hospit
institut
region
pediatr
referr
center
immunocompromis
patient
seen
follow
institut
larg
geograph
referr
area
possibl
children
seen
elsewher
therefor
studi
could
bias
toward
detect
sever
hmpv
diseas
also
possibl
subset
earlier
hmpvposit
case
miss
use
dfa
compar
pcr
sensit
detect
techniqu
furthermor
unabl
captur
data
time
clinic
present
obtain
full
inform
regard
clinic
decisionmak
administr
ribavirin
andor
ivig
therefor
comparison
outcom
patient
receiv
treatment
problemat
potenti
benefit
therapi
readili
evalu
unlik
previou
hmpv
studi
conduct
adult
hsct
recipi
patient
itali
assess
hmpv
shed
asymptomat
patient
unfortun
comment
rate
symptomat
versu
asymptomat
shed
hmpv
patient
final
limit
abil
classifi
diseas
sever
base
hypoxemia
patient
oxygen
satur
chart
suspect
higher
proport
patient
would
classifi
sever
diseas
use
criteria
use
papenburg
et
al
although
patient
identifi
acquir
hmpv
infect
nosocomi
vast
major
patient
seen
frequent
outpati
basi
clinic
blood
draw
intervent
chemotherapi
make
difficult
differenti
true
communityacquir
diseas
acquir
hospit
set
prospect
random
studi
ribavirin
ivig
administr
newer
therapeut
agent
develop
treatment
paramyxoviru
infect
would
help
given
high
morbid
associ
hmpv
immunocompromis
popul
particular
studi
use
novel
agent
includ
fusion
inhibitor
could
studi
popul
given
potenti
serv
postexposur
prophylaxi
highrisk
individu
document
sever
hmpv
diseas
immunocompromis
children
support
previou
data
document
sever
fatal
hmpv
diseas
report
adult
hsct
recipi
highlight
need
treatment
option
popul
